Table 2.
Viability of primary AML cells treated with alantolactone
| AML specimens | Viability of CD34+CD38− (%)a | ||
|---|---|---|---|
| 2.5 μM | 5 μM | 10 μM | |
| AML1 | 67.9 | 10.0 | 2.1 |
| AML2 | 74.5 | 62.1 | 43.7 |
| AML3 | 75.9 | 19.6 | 1.5 |
| AML4 | 17.9 | 10.4 | 8.9 |
| AML5 | 58.8 | 46.3 | 24.7 |
| AML6 | 85.4 | 70.6 | 66.9 |
| AML7 | 40.3 | 9.6 | 4.6 |
| AML8 | 86.1 | 29.8 | 3.2 |
| AML9 | 0.0 | 0.0 | 0.0 |
| AML10 | 19.6 | 15.0 | 7.2 |
| AML11 | 53.3 | 6.4 | 5.0 |
| AML12 | 6.6 | 3.2 | 2.1 |
| AML13 | 6.2 | 2.0 | 0.0 |
| AML14 | 35.4 | 28.4 | 25.5 |
| AML15 | 91.7 | 31.6 | 26.6 |
| AML16 | 76.3 | 35.3 | 6.0 |
| AML17 | 37.5 | 28.9 | 8.9 |
| AML18 | 85.5 | 70.5 | 67.0 |
All values were carried out as triplicate
aThe percentage of viability was normalized to untreated control